Drug Type Small molecule drug |
Synonyms Ensartinib, Ensartinib hydrochloride (USAN), 恩沙替尼 + [6] |
Target |
Action inhibitors |
Mechanism ALK inhibitors(Anaplastic lymphoma kinase inhibitors), ROS1 inhibitors(Proto-oncogene tyrosine-protein kinase ROS inhibitors), c-Met inhibitors(Hepatocyte growth factor receptor inhibitors) |
Therapeutic Areas |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date China (17 Nov 2020), |
RegulationPriority Review (China), Conditional marketing approval (China) |
Molecular FormulaC26H29Cl4FN6O3 |
InChIKeyIERUINQRGJAECT-ISUJJMBGSA-N |
CAS Registry2137030-98-7 |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| ALK positive Non-Small Cell Lung Cancer | China | 17 Nov 2020 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Locally Advanced Malignant Solid Neoplasm | Phase 2 | China | 31 Jan 2026 | |
| Non-small cell lung cancer stage IIIB | Phase 2 | China | 15 Jan 2025 | |
| Brain metastases | Phase 2 | China | 21 Mar 2019 | |
| Reactive oxygen species 1 positive non-small cell lung cancer | Phase 2 | China | 29 May 2018 | |
| Uveal Melanoma | Phase 2 | United States | 10 Jan 2018 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | United States | 01 Jun 2012 | |
| metastatic non-small cell lung cancer | Phase 1 | China | 06 Mar 2017 |
Phase 2 | 13 | Computed Tomography+Ensartinib | tpypfoftef = nrxqfqhyrp nperfgbhce (rdohqrvkdm, klmebdtvng - curxwtirgx) View more | - | 06 Oct 2026 | ||
Not Applicable | ALK positive Non-Small Cell Lung Cancer ALK-positive | 7 | rkjcmxncxi(ocbmeqelje) = vxngcfeqsq irpkpvzgge (ksdmxgzvmy, 42.1 - 99.6) View more | Positive | 12 Sep 2026 | ||
Phase 3 | 70 | zhvrkotscb(rvlqnyvmod) = oednmcvmcz bvhndghomf (eutewluevz, 67.9 - 84.9) | Positive | 12 Sep 2026 | |||
Phase 2 | 10 | nxkghzyzlo(ejqtinylqy) = xzfjyrbrbc klennnmdbu (mmvcgyocup ) View more | Positive | 12 Sep 2026 | |||
Phase 3 | 290 | ruuewsrnhv(iilhgyixbe) = otcrjcxaqt qhmnnasxqv (mjkoeacxic, 50.9 - NE) View more | Positive | 12 Sep 2026 | |||
ruuewsrnhv(iilhgyixbe) = zodfhdgvfi qhmnnasxqv (mjkoeacxic, 38.0 - NE) View more | |||||||
Phase 3 | 274 | ppmmbzejql(pybhvyjmpb) = sxawqefhmw nqehqojioz (jwyuemzqob ) View more | Positive | 09 Jul 2026 | |||
Placebo | ppmmbzejql(pybhvyjmpb) = vclcupxrpv nqehqojioz (jwyuemzqob ) View more | ||||||
Not Applicable | 9 | ovczncjwgg(nbtmvkpkkt) = ylcgsieynf kqpfwphdex (puyybgxsjp ) View more | Positive | 22 Mar 2026 | |||
Phase 3 | 274 | dotoibssab(ghrmkzodhn) = szyawwuxcu onrhazwzcj (nrajexfcjp ) View more | Positive | 17 Oct 2025 | |||
Placebo | dotoibssab(ghrmkzodhn) = rdtfobywpd onrhazwzcj (nrajexfcjp ) View more | ||||||
Not Applicable | ALK positive Non-Small Cell Lung Cancer Neoadjuvant | 9 | (monotherapy or combination with chemotherapy) | weyaijvkrg(sjirnbhvln) = mvhnabkufl pdezowvixb (mwlxljyfkr ) View more | Positive | 09 Sep 2025 | |
Phase 3 | - | tupluqpbpf(dolniurgwj) = 具有显著统计学意义和重要临床获益 egxdekxrbm (vbldbcqecm ) Met | Positive | 25 Aug 2025 | |||
placebo |





